The Indian government has officially released the NLEM List 2025, marking a crucial development in the country’s healthcare affordability and accessibility. The National List of Essential Medicines (NLEM) is updated by the Ministry of Health and Family Welfare to reflect current healthcare needs and disease patterns. These are life-saving medicines that must be available at all times, in adequate amounts, and at affordable prices.
The NLEM List 2025 now features a revised catalog of 612 essential medicines, including newly added drugs for cancer, diabetes, infectious diseases, mental health, and chronic ailments. This update ensures a broader range of crucial treatments will fall under government price control through the National Pharmaceutical Pricing Authority (NPPA), thereby reducing treatment costs for millions of Indians.
This major revision reflects India’s commitment to universal health coverage and making quality drugs available to everyone, irrespective of socioeconomic status.
Key Highlights of the NLEM List 2025
The NLEM List 2025 is a vital policy tool used to regulate the prices of essential drugs under the Drug Price Control Order (DPCO). Here’s what’s new in the latest update:
-
34 new medicines added to the list
-
26 medicines removed due to redundancy or better alternatives
-
Significant additions include insulin glargine, teneligliptin, bedaquiline, oxaliplatin, and newer antipsychotics
-
Inclusion of drugs for rare diseases, reflecting expanding public health focus
-
Price caps to be revised and notified soon by NPPA
These changes are based on expert reviews, scientific evidence, disease burden, and affordability considerations.
Newly Added Medicines and Their Purpose
The following are some of the important additions to the NLEM List 2025, categorized by disease or use:
| Medicine Name | Therapeutic Use |
|---|---|
| Insulin Glargine | Long-acting insulin for diabetes |
| Bedaquiline | Drug-resistant TB treatment |
| Oxaliplatin | Cancer (colorectal) chemotherapy |
| Teneligliptin | Type 2 diabetes management |
| Buprenorphine + Naloxone | Opioid dependence |
| Levonorgestrel-IUD | Contraception |
| Aripiprazole | Schizophrenia and bipolar disorder |
These additions ensure patients have access to the most relevant and modern treatments under price control frameworks.
Impact of NLEM List 2025 on Public Healthcare
The update to the NLEM List 2025 is a game-changer in India’s healthcare landscape. Here’s why it matters:
-
Price control of listed drugs helps bring down the cost of treatment
-
Ensures wider access to essential and advanced drugs, especially in rural and government hospitals
-
Boosts availability in public health institutions, improving public trust in government healthcare
-
Encourages domestic manufacturing of listed essential drugs
-
Supports Jan Aushadhi Kendras, which align their pricing based on the NLEM
-
Reduces out-of-pocket expenditure on medicines for economically weaker sections
Doctors in public hospitals are encouraged to prescribe only NLEM-listed medicines, making these updates directly impactful to millions of patients.
Government Strategy Behind the NLEM Update
The revision of the NLEM List 2025 follows a careful and scientific process. Here’s how the final list is created:
-
Input from drug experts, industry leaders, and public health institutions
-
Consideration of disease burden and medicine usage trends
-
Comparison with international essential medicine lists (like WHO’s)
-
Availability of safer, more effective alternatives for outdated drugs
-
Approval from the Standing National Committee on Medicines
The goal is to maintain a list that meets basic, cost-effective, evidence-based, and rational treatment needs of the Indian population.
FAQs
What is the purpose of the NLEM List 2025?
The NLEM List 2025 defines essential medicines that are necessary for public health and must be made available at affordable prices under price control regulations.
How many drugs are there in the updated list?
The updated list includes 612 essential medicines, with 34 new additions and 26 removals.
Are NLEM-listed medicines cheaper?
Yes. All medicines on the NLEM list are subject to price regulation by NPPA, ensuring affordability for patients.
Who benefits from the NLEM List 2025?
Patients, especially from low-income or rural backgrounds, benefit as these drugs are made available at low costs in government hospitals and Jan Aushadhi Kendras.
Can private hospitals use NLEM medicines?
Yes. Private hospitals and pharmacies can stock and use these medicines, and their prices are capped to ensure fair access.
Click here to know more.